β-Sitosterol and Gemcitabine Exhibit Synergistic Anti-pancreatic Cancer Activity by Modulating Apoptosis and Inhibiting Epithelial–Mesenchymal Transition by Deactivating Akt/GSK-3β Signaling
β-sitosterol (BS), a major bioactive constituent present in plants, has shown potent anti-cancer activity against many human cancer cells, but its activity in pancreatic cancer (PC) cells has rarely been reported. Gemcitabine (GEM) is one of the first-line drugs for PC therapy, however, the treatmen...
Saved in:
| Published in | Frontiers in pharmacology Vol. 9; p. 1525 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
Frontiers Media S.A
08.01.2019
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | β-sitosterol (BS), a major bioactive constituent present in plants, has shown potent anti-cancer activity against many human cancer cells, but its activity in pancreatic cancer (PC) cells has rarely been reported. Gemcitabine (GEM) is one of the first-line drugs for PC therapy, however, the treatment effect is not sustained due to prolonged drug resistance. In this study, we firstly studied the anti-PC activity and the mechanism of BS alone and in combination with GEM
in vitro
and
in vivo
. BS effectively inhibited the growth of PC cell lines by inhibiting proliferation, inducing G0/G1 phase arrest and apoptosis, suppressed the NF- kB activity, and increased expression of the protein Bax but decreased expression of the protein Bcl-2. Moreover, BS inhibited migration and invasion and downregulated epithelial–mesenchymal transition (EMT) markers and AKT/GSK-3β signaling pathways. Furthermore, the combination of BS and GEM exhibited a significant synergistic effect in MIAPaCa-2 and BXPC-3 cells. More importantly, the combined treatment with BS and GEM lead to significant growth inhibition of PC xenografts. Overall, our data revealed a promising treatment option for PC by the combination therapy of BS and GEM. |
|---|---|
| AbstractList | β-sitosterol (BS), a major bioactive constituent present in plants, has shown potent anti-cancer activity against many human cancer cells, but its activity in pancreatic cancer (PC) cells has rarely been reported. Gemcitabine (GEM) is one of the first-line drugs for PC therapy, however, the treatment effect is not sustained due to prolonged drug resistance. In this study, we firstly studied the anti-PC activity and the mechanism of BS alone and in combination with GEM
and
. BS effectively inhibited the growth of PC cell lines by inhibiting proliferation, inducing G0/G1 phase arrest and apoptosis, suppressed the NF- kB activity, and increased expression of the protein Bax but decreased expression of the protein Bcl-2. Moreover, BS inhibited migration and invasion and downregulated epithelial-mesenchymal transition (EMT) markers and AKT/GSK-3β signaling pathways. Furthermore, the combination of BS and GEM exhibited a significant synergistic effect in MIAPaCa-2 and BXPC-3 cells. More importantly, the combined treatment with BS and GEM lead to significant growth inhibition of PC xenografts. Overall, our data revealed a promising treatment option for PC by the combination therapy of BS and GEM. β-sitosterol (BS), a major bioactive constituent present in plants, has shown potent anti-cancer activity against many human cancer cells, but its activity in pancreatic cancer (PC) cells has rarely been reported. Gemcitabine (GEM) is one of the first-line drugs for PC therapy, however, the treatment effect is not sustained due to prolonged drug resistance. In this study, we firstly studied the anti-PC activity and the mechanism of BS alone and in combination with GEM in vitro and in vivo. BS effectively inhibited the growth of PC cell lines by inhibiting proliferation, inducing G0/G1 phase arrest and apoptosis, suppressed the NF- kB activity, and increased expression of the protein Bax but decreased expression of the protein Bcl-2. Moreover, BS inhibited migration and invasion and downregulated epithelial-mesenchymal transition (EMT) markers and AKT/GSK-3β signaling pathways. Furthermore, the combination of BS and GEM exhibited a significant synergistic effect in MIAPaCa-2 and BXPC-3 cells. More importantly, the combined treatment with BS and GEM lead to significant growth inhibition of PC xenografts. Overall, our data revealed a promising treatment option for PC by the combination therapy of BS and GEM.β-sitosterol (BS), a major bioactive constituent present in plants, has shown potent anti-cancer activity against many human cancer cells, but its activity in pancreatic cancer (PC) cells has rarely been reported. Gemcitabine (GEM) is one of the first-line drugs for PC therapy, however, the treatment effect is not sustained due to prolonged drug resistance. In this study, we firstly studied the anti-PC activity and the mechanism of BS alone and in combination with GEM in vitro and in vivo. BS effectively inhibited the growth of PC cell lines by inhibiting proliferation, inducing G0/G1 phase arrest and apoptosis, suppressed the NF- kB activity, and increased expression of the protein Bax but decreased expression of the protein Bcl-2. Moreover, BS inhibited migration and invasion and downregulated epithelial-mesenchymal transition (EMT) markers and AKT/GSK-3β signaling pathways. Furthermore, the combination of BS and GEM exhibited a significant synergistic effect in MIAPaCa-2 and BXPC-3 cells. More importantly, the combined treatment with BS and GEM lead to significant growth inhibition of PC xenografts. Overall, our data revealed a promising treatment option for PC by the combination therapy of BS and GEM. β-sitosterol (BS), a major bioactive constituent present in plants, has shown potent anti-cancer activity against many human cancer cells, but its activity in pancreatic cancer (PC) cells has rarely been reported. Gemcitabine (GEM) is one of the first-line drugs for PC therapy, however, the treatment effect is not sustained due to prolonged drug resistance. In this study, we firstly studied the anti-PC activity and the mechanism of BS alone and in combination with GEM in vitro and in vivo . BS effectively inhibited the growth of PC cell lines by inhibiting proliferation, inducing G0/G1 phase arrest and apoptosis, suppressed the NF- kB activity, and increased expression of the protein Bax but decreased expression of the protein Bcl-2. Moreover, BS inhibited migration and invasion and downregulated epithelial–mesenchymal transition (EMT) markers and AKT/GSK-3β signaling pathways. Furthermore, the combination of BS and GEM exhibited a significant synergistic effect in MIAPaCa-2 and BXPC-3 cells. More importantly, the combined treatment with BS and GEM lead to significant growth inhibition of PC xenografts. Overall, our data revealed a promising treatment option for PC by the combination therapy of BS and GEM. β-sitosterol (BS), a major bioactive constituent present in plants, has shown potent anti-cancer activity against many human cancer cells, but its activity in pancreatic cancer (PC) cells has rarely been reported. Gemcitabine (GEM) is one of the first-line drugs for PC therapy, however, the treatment effect is not sustained due to prolonged drug resistance. In this study, we firstly studied the anti-PC activity and the mechanism of BS alone and in combination with GEM in vitro and in vivo. BS effectively inhibited the growth of PC cell lines by inhibiting proliferation, inducing G0/G1 phase arrest and apoptosis, suppressed the NF- kB activity, and increased expression of the protein Bax but decreased expression of the protein Bcl-2. Moreover, BS inhibited migration and invasion and downregulated epithelial–mesenchymal transition (EMT) markers and AKT/GSK-3β signaling pathways. Furthermore, the combination of BS and GEM exhibited a significant synergistic effect in MIAPaCa-2 and BXPC-3 cells. More importantly, the combined treatment with BS and GEM lead to significant growth inhibition of PC xenografts. Overall, our data revealed a promising treatment option for PC by the combination therapy of BS and GEM. |
| Author | Song, Yu-jun Xu, Jing-wen Ma, Zhan-jun Cao, Zhang-qi Shi, An-chen Zhang, Guang-ru Wang, Xue-xi Lu, Li Li, Xiao-bin Wang, Yan |
| AuthorAffiliation | 1 School of Basic Medical Sciences, Lanzhou University , Lanzhou , China 2 Qinghai Hospital of Traditional Chinese Medicine , Xining , China 3 The Second Clinical School, Lanzhou University , Lanzhou , China |
| AuthorAffiliation_xml | – name: 2 Qinghai Hospital of Traditional Chinese Medicine , Xining , China – name: 3 The Second Clinical School, Lanzhou University , Lanzhou , China – name: 1 School of Basic Medical Sciences, Lanzhou University , Lanzhou , China |
| Author_xml | – sequence: 1 givenname: Zhang-qi surname: Cao fullname: Cao, Zhang-qi – sequence: 2 givenname: Xue-xi surname: Wang fullname: Wang, Xue-xi – sequence: 3 givenname: Li surname: Lu fullname: Lu, Li – sequence: 4 givenname: Jing-wen surname: Xu fullname: Xu, Jing-wen – sequence: 5 givenname: Xiao-bin surname: Li fullname: Li, Xiao-bin – sequence: 6 givenname: Guang-ru surname: Zhang fullname: Zhang, Guang-ru – sequence: 7 givenname: Zhan-jun surname: Ma fullname: Ma, Zhan-jun – sequence: 8 givenname: An-chen surname: Shi fullname: Shi, An-chen – sequence: 9 givenname: Yan surname: Wang fullname: Wang, Yan – sequence: 10 givenname: Yu-jun surname: Song fullname: Song, Yu-jun |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30670971$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1ks9uEzEQxleoiJbSOye0Ry6betfefxekqJQS0YpDytmatWcTF8debKciN96BN-kj8AB9CJ4EbxKqFglfPJ755jeW_b1MDow1mCSvczKhtGlP-2EJblKQvJmQvCzKZ8lRXlU0a5u8OHgUHyYn3t-QuGjb0oq9SA4pqWrS1vlR8uv-LpurYH1AZ3UKRqYXuBIqQKcMpuffl6pTIZ1vDLqF8kGJdGqCygYwwiGM57MYokunIqhbFTZpt0mvrFzrWDSLdDrYIeKV37JnZssbC-eDCkvUCvTvHz-v0KMRy80KdHrtwPiosWZEvUcYwXvY13B6Mf-U0fu7dK4WBnTMvkqe96A9nuz34-TLh_Prs4_Z5eeL2dn0MhOsKkJGqQCsqaSSdKyvCtIBIJM1K4Ew0tTYtjmpRSeBEUBRyKYsmKAlpbKrmOzocTLbcaWFGz44tQK34RYU3yasW3Bw8UE08j5nsYUClgCsRtEUZSV6WcuGkr4vRGS927GGdbdCKdAEB_oJ9GnFqCVf2FteUZqzso2At3uAs9_W6ANfKS9QazBo154Xed2yoqrKOkrfPJ71MOSvCaKA7ATCWe8d9g-SnPDRanxrNT5ajW-tFluqf1pGy4x_Fm-r9P8b_wCEQuHd |
| CitedBy_id | crossref_primary_10_1016_j_envres_2023_117443 crossref_primary_10_1177_03946320241263352 crossref_primary_10_1002_ptr_8061 crossref_primary_10_1002_ddr_70078 crossref_primary_10_3390_molecules24224139 crossref_primary_10_1002_cam4_7314 crossref_primary_10_3389_fcell_2022_753425 crossref_primary_10_1016_j_ejphar_2022_175411 crossref_primary_10_2174_1871527319999200730214807 crossref_primary_10_1155_2021_6641838 crossref_primary_10_1002_lipd_12409 crossref_primary_10_1186_s12906_019_2580_y crossref_primary_10_1016_j_ijpharm_2023_123599 crossref_primary_10_1007_s00210_020_01810_8 crossref_primary_10_1155_2022_3758219 crossref_primary_10_3390_ph17070860 crossref_primary_10_1186_s12906_021_03215_3 crossref_primary_10_3389_fphar_2020_00451 crossref_primary_10_1007_s13205_023_03673_1 crossref_primary_10_1007_s40495_024_00383_x crossref_primary_10_3724_abbs_2023251 crossref_primary_10_1155_2022_6229462 crossref_primary_10_1021_acs_jafc_9b02730 crossref_primary_10_1111_cbdd_14493 crossref_primary_10_1155_2023_2677020 crossref_primary_10_1002_bab_2102 crossref_primary_10_1016_j_ejphar_2020_173225 crossref_primary_10_2174_1871520621666210427104804 crossref_primary_10_1007_s13577_024_01081_y crossref_primary_10_1016_j_cbi_2022_110117 crossref_primary_10_1007_s10555_023_10161_8 crossref_primary_10_1266_ggs_24_00108 crossref_primary_10_1007_s12672_024_01624_7 crossref_primary_10_3389_fonc_2022_926975 crossref_primary_10_3390_pharmaceutics14061214 crossref_primary_10_1080_10408398_2020_1835820 crossref_primary_10_3390_molecules25194435 crossref_primary_10_1016_j_cellsig_2022_110585 crossref_primary_10_1016_j_lwt_2024_116786 crossref_primary_10_1016_j_bmc_2025_118085 crossref_primary_10_1016_j_jep_2022_115516 crossref_primary_10_1155_2021_4475192 |
| Cites_doi | 10.1016/j.cca.2014.12.041 10.1016/j.canlet.2008.01.032 10.1016/j.jpba.2018.07.023 10.1158/1078-0432.CCR-06-0196 10.1016/j.bbagen.2014.07.018 10.1242/jcs.00384 10.1016/j.ceb.2005.08.001 10.1093/carcin/bgx065 10.1038/s41467-018-07472-8 10.1016/j.canlet.2018.09.013 10.1038/s41598-018-2031-6 10.1158/1940-6207.CAPR-14-0136 10.3389/fphar.2018.00664 10.1245/s10434-007-9540-3 10.3389/fphar.2016.00463 10.1016/j.canlet.2007.09.015 10.1038/nrc.2017.118 10.1016/j.bcp 10.1016/j.cbi.2018.05.007 10.1016/j.jbior.2014.09.016 10.1016/j.canlet.2014.11.044 10.1308/rcsann.2016.0340 10.1016/S0092-8674(02)00685-2 10.1038/nrd.2015.13 10.1080/01635581.2015.1087042 10.1186/s13045-016-0371-1 10.1126/science.1066237 10.1111/j.1365-2354.2007.00865.x 10.1007/s10495-015-1169-2 10.1016/j.biocel.2007.07.011 10.1586/14737140.8.6.993 10.1038/s41388-018-0392-z 10.1093/annonc/mdq292 10.3892/ol.2015.3459 10.1074/jbc.M113.450106 10.1097/MPA.0b013e318193a074 10.1016/j.ejca.2013.07.146 10.1111/j.1349-7006.2011.02154.x 10.1016/S0140-6736(16)00141-0 10.1016/j.canlet.2017.09.018 10.1158/0008-5472.CAN-09-1947 10.1186/2045-3701-4-59 10.1016/j.cell.2004.11.012 10.1016/j.ctrv.2013.05.008 10.1038/ng0897-358 10.4103/0974-8520.100295 10.1056/NEJMra0901557 10.1186/1472-6882-10-24 |
| ContentType | Journal Article |
| Copyright | Copyright © 2019 Cao, Wang, Lu, Xu, Li, Zhang, Ma, Shi, Wang and Song. 2019 Cao, Wang, Lu, Xu, Li, Zhang, Ma, Shi, Wang and Song |
| Copyright_xml | – notice: Copyright © 2019 Cao, Wang, Lu, Xu, Li, Zhang, Ma, Shi, Wang and Song. 2019 Cao, Wang, Lu, Xu, Li, Zhang, Ma, Shi, Wang and Song |
| DBID | AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.3389/fphar.2018.01525 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1663-9812 |
| ExternalDocumentID | oai_doaj_org_article_f1464d3ae5aa47ec8256cfd7d830ff2c PMC6331459 30670971 10_3389_fphar_2018_01525 |
| Genre | Journal Article |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E O5R O5S OK1 P2P PGMZT RNS RPM IPNFZ NPM RIG 7X8 5PM |
| ID | FETCH-LOGICAL-c462t-33cae73d3d0b4f620baae4d745a04087e99107cbda40aec2d8524c3533db64db3 |
| IEDL.DBID | DOA |
| ISSN | 1663-9812 |
| IngestDate | Wed Aug 27 01:25:17 EDT 2025 Thu Aug 21 14:13:31 EDT 2025 Fri Jul 11 08:57:05 EDT 2025 Thu Apr 03 06:55:27 EDT 2025 Tue Jul 01 02:25:31 EDT 2025 Thu Apr 24 22:50:57 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | GSK-3β pancreatic cancer β-sitosterol apoptosis AKT gemcitabine EMT |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c462t-33cae73d3d0b4f620baae4d745a04087e99107cbda40aec2d8524c3533db64db3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology Edited by: Olivier Cuvillier, The National Center for Scientific Research (CNRS), France Reviewed by: Julie Guillermet-Guibert, INSERM U1037 Centre de Recherche en Cancérologie de Toulouse, France; Kuzhuvelil B. Harikumar, Rajiv Gandhi Centre for Biotechnology, India |
| OpenAccessLink | https://doaj.org/article/f1464d3ae5aa47ec8256cfd7d830ff2c |
| PMID | 30670971 |
| PQID | 2179426657 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_f1464d3ae5aa47ec8256cfd7d830ff2c pubmedcentral_primary_oai_pubmedcentral_nih_gov_6331459 proquest_miscellaneous_2179426657 pubmed_primary_30670971 crossref_primary_10_3389_fphar_2018_01525 crossref_citationtrail_10_3389_fphar_2018_01525 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2019-01-08 |
| PublicationDateYYYYMMDD | 2019-01-08 |
| PublicationDate_xml | – month: 01 year: 2019 text: 2019-01-08 day: 08 |
| PublicationDecade | 2010 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Frontiers in pharmacology |
| PublicationTitleAlternate | Front Pharmacol |
| PublicationYear | 2019 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | McCubrey (B27) 2015; 57 Meng (B28) 2018; 37 Massihnia (B26) 2017; 10 Javle (B16) 2007; 14 Bartek (B3); 16 Shin (B38) 2018; 152 Strouch (B39) 2009; 38 Antoniou (B1) 2014; 40 Kang (B18) 2018; 438 Naiara (B31) 2018; 9 Liu (B23) 2016; 288 Liu (B24) 2014; 1840 Pu (B34) 2008; 17 Rocha-Lima (B36) 2008; 8 Zhang (B46) 2015; 444 Ougolkov (B33) 2006; 12 Bartek (B2); 294 Kamisawa (B17) 2016; 388 Fan (B11) 2018; 9 Yoshida (B43) 2017; 38 Bin Sayeed (B5) 2015; 67 Chan (B6) 2014; 4 Hidalgo (B14) 2010; 362 Millimouno (B29) 2014; 7 Moon (B30) 2008; 264 Huber (B15) 2005; 17 Knudson (B20) 1997; 16 Elshaer (B10) 2017; 99 Gali-Muhtasib (B12) 2015; 20 Chen (B7) 2018; 159 Guarino (B13) 2007; 39 Savagner (B37) 2010; 21 Rajavel (B35) 2018; 8 Omar (B32) 2016; 7 Wang (B41) 2018; 290 Marcucci (B25) 2016; 15 Thomas (B40) 2018; 18 Yoshimura (B44) 2005; 120 Doble (B9) 2003; 116 Liu (B22) 2002; 108 Zhang (B47) 2012; 103 Katiyar (B19) 2012; 33 Lee (B21) 2008; 259 Chou (B8) 2010; 70 Zhang (B45) 2013; 49 Zhou (B48) 2015; 358 Basker (B4) 2010; 10 Zhuang (B49) 2017; 411 Ye (B42) 2015; 10 33658921 - Front Pharmacol. 2020 Nov 20;11:565535 |
| References_xml | – volume: 444 start-page: 182 year: 2015 ident: B46 article-title: PI3K/Akt signaling in osteosarcoma. publication-title: Clin. Chim. Acta doi: 10.1016/j.cca.2014.12.041 – volume: 264 start-page: 181 year: 2008 ident: B30 article-title: β-Sitosterol induces G2/M arrest, endoreduplication, and apoptosis through the Bcl-2 and PI3K/Akt signaling pathways. publication-title: Cancer Lett. doi: 10.1016/j.canlet.2008.01.032 – volume: 159 start-page: 490 year: 2018 ident: B7 article-title: Simultaneous determination of fourteen compounds of Hedyotis diffusa Willd extract in rats by UHPLC-MS/MS method: application to pharmacokinetics and tissue distribution study. publication-title: J. Pharm. Biomed. Anal. doi: 10.1016/j.jpba.2018.07.023 – volume: 12 start-page: 5074 year: 2006 ident: B33 article-title: Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: association with kinase activity and tumor dedifferentiation. publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-06-0196 – volume: 1840 start-page: 3096 year: 2014 ident: B24 article-title: AKT/GSK-3β regulates stability and transcription of snail which is crucial for bFGF-induced epithelial–mesenchymal transition of prostate cancer cells. publication-title: Biochim. Biophys. Acta doi: 10.1016/j.bbagen.2014.07.018 – volume: 116 start-page: 1175 year: 2003 ident: B9 article-title: GSK-3: tricks of the trade for a multi-tasking kinase. publication-title: J. Cell Sci. doi: 10.1242/jcs.00384 – volume: 17 start-page: 548 year: 2005 ident: B15 article-title: Molecular requirements for epithelial–mesenchymal transition during tumor progression. publication-title: Curr. Opin. Cell Biol. doi: 10.1016/j.ceb.2005.08.001 – volume: 38 start-page: 1036 year: 2017 ident: B43 article-title: Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZ-H2, and the lncRNA PVT1 expression. publication-title: Carcinogenesis doi: 10.1093/carcin/bgx065 – volume: 9 year: 2018 ident: B31 article-title: Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. publication-title: Nat. Commun. doi: 10.1038/s41467-018-07472-8 – volume: 438 start-page: 174 year: 2018 ident: B18 article-title: KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer. publication-title: Cancer Lett. doi: 10.1016/j.canlet.2018.09.013 – volume: 8 year: 2018 ident: B35 article-title: β-Sitosterol targets Trx/Trx1 reductase to induce apoptosis in A549 cells via ROS mediated mitochondrial dysregulation and p53 activation. publication-title: Sci. Rep. doi: 10.1038/s41598-018-2031-6 – volume: 7 start-page: 1081 year: 2014 ident: B29 article-title: Targeting apoptosis pathways in cancer and perspectives with natural compounds from mother nature. publication-title: Cancer Prev. Res. doi: 10.1158/1940-6207.CAPR-14-0136 – volume: 9 year: 2018 ident: B11 article-title: Trimebutine promotes glioma cell apoptosis as a potential anti-tumor agent. publication-title: Front. Pharmacol. doi: 10.3389/fphar.2018.00664 – volume: 14 start-page: 3527 year: 2007 ident: B16 article-title: Epithelial–mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer. publication-title: Ann. Surg. Oncol. doi: 10.1245/s10434-007-9540-3 – volume: 7 year: 2016 ident: B32 article-title: OSU-2S/Sorafenib synergistic antitumor combination against hepatocellular carcinoma: the role of PKCδ/p53. publication-title: Front. Pharmacol. doi: 10.3389/fphar.2016.00463 – volume: 259 start-page: 39 year: 2008 ident: B21 article-title: Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer. publication-title: Cancer Lett. doi: 10.1016/j.canlet.2007.09.015 – volume: 18 start-page: 128 year: 2018 ident: B40 article-title: EMT in cancer. publication-title: Nat. Rev. Cancer doi: 10.1038/nrc.2017.118 – volume: 152 start-page: 60 year: 2018 ident: B38 article-title: Anti-tumour effects of beta-sitosterol are mediated by AMPK/PTEN/HSP90 axis in AGS human gastric adenocarcinoma cells and xenograft mouse models. publication-title: Biochem. Pharmacol. doi: 10.1016/j.bcp – volume: 290 start-page: 44 year: 2018 ident: B41 article-title: Licoricidin enhances gemcitabine-induced cytotoxicity in osteosarcoma cells by suppressing the Akt and NF-κB signal pathways. publication-title: Chem. Biol. Interact doi: 10.1016/j.cbi.2018.05.007 – volume: 57 start-page: 75 year: 2015 ident: B27 article-title: Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis. publication-title: Adv. Biol. Regul. doi: 10.1016/j.jbior.2014.09.016 – volume: 358 start-page: 124 year: 2015 ident: B48 article-title: CxCR2/CxCL5 axis contributes to epithelial–mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3β/Snail signaling. publication-title: Cancer Lett. doi: 10.1016/j.canlet.2014.11.044 – volume: 99 start-page: 101 year: 2017 ident: B10 article-title: A systematic review of the prognostic value of lymph node ratio, number of positive nodes and total nodes examined in pancreatic ductal adenocarcinoma. publication-title: Ann. R. Coll. Surg. Engl. doi: 10.1308/rcsann.2016.0340 – volume: 108 start-page: 837 year: 2002 ident: B22 article-title: Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. publication-title: Cell doi: 10.1016/S0092-8674(02)00685-2 – volume: 15 start-page: 311 year: 2016 ident: B25 article-title: Epithelial-mesenchymal transition: a new target in anticancer drug discovery. publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd.2015.13 – volume: 67 start-page: 1214 year: 2015 ident: B5 article-title: Beta-sitosterol: a promising but orphan nutraceutical to fight against cancer. publication-title: Nutr. Cancer doi: 10.1080/01635581.2015.1087042 – volume: 10 year: 2017 ident: B26 article-title: Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer. publication-title: J. Hematol. Oncol. doi: 10.1186/s13045-016-0371-1 – volume: 294 start-page: 66 ident: B2 article-title: Cell cycle: order from destruction. publication-title: Science doi: 10.1126/science.1066237 – volume: 16 start-page: 117 ident: B3 article-title: Pathways governing G1/S transition and their response to DNA damage. publication-title: FEBS Lett. – volume: 17 start-page: 340 year: 2008 ident: B34 article-title: The determinants of traditional Chinese medicine and acupuncture utilization for cancer patients with simultaneous conventional treatment. publication-title: Eur. J. Cancer Care doi: 10.1111/j.1365-2354.2007.00865.x – volume: 20 start-page: 1531 year: 2015 ident: B12 article-title: Cell death mechanisms of plant-derived anticancer drugs: beyond apoptosis. publication-title: Apoptosis doi: 10.1007/s10495-015-1169-2 – volume: 39 start-page: 2153 year: 2007 ident: B13 article-title: Epithelial-mesenchymal transition and tumour invasion. publication-title: Int. J. Biochem. Cell. Biol. doi: 10.1016/j.biocel.2007.07.011 – volume: 8 start-page: 993 year: 2008 ident: B36 article-title: Novel advances in pancreatic cancer treatment. publication-title: Expert Rev. Anticancer Ther. doi: 10.1586/14737140.8.6.993 – volume: 37 start-page: 5843 year: 2018 ident: B28 article-title: Abrogation of glutathione peroxidase-1 drives EMT and chemoresistance in pancreatic cancer by activating ROS-mediated Akt/GSK3β/Snail signaling. publication-title: Oncogene doi: 10.1038/s41388-018-0392-z – volume: 21 start-page: vii89 year: 2010 ident: B37 article-title: The epithelial-mesenchymal transition (EMT) phenomenon. publication-title: Ann. Oncol. doi: 10.1093/annonc/mdq292 – volume: 10 start-page: 1240 year: 2015 ident: B42 article-title: Traditional Chinese medicine in the prevention and treatment of cancer and cancer metastasis. publication-title: Oncol. Lett. doi: 10.3892/ol.2015.3459 – volume: 288 start-page: 29965 year: 2016 ident: B23 article-title: Succinate dehydrogenase 5 (SDH5) regulates glycogen synthase kinase 3β-β-catenin-mediated lung cancer metastasis. publication-title: J. Biol. Chem. doi: 10.1074/jbc.M113.450106 – volume: 38 start-page: 409 year: 2009 ident: B39 article-title: The flavonoid apigenin potentiates the growth inhibitory effects of gemcitabine and abrogates gemcitabine resistance in human pancreatic cancer cells. publication-title: Pancreas doi: 10.1097/MPA.0b013e318193a074 – volume: 49 start-page: 3900 year: 2013 ident: B45 article-title: Nir1 promotes invasion of breast cancer cells by binding to chemokine (C-C motif) ligand 18 through the PI3K/Akt/GSK3β/Snail signalling pathway. publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2013.07.146 – volume: 103 start-page: 181 year: 2012 ident: B47 article-title: Notch1 promotes glioma cell migration and invasion by stimulating β-catenin and NF-κb signaling via AKT activation. publication-title: Cancer Sci. doi: 10.1111/j.1349-7006.2011.02154.x – volume: 388 start-page: 73 year: 2016 ident: B17 article-title: Pancreatic cancer. publication-title: Lancet doi: 10.1016/S0140-6736(16)00141-0 – volume: 411 start-page: 44 year: 2017 ident: B49 article-title: NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-kB activation. publication-title: Cancer Lett. doi: 10.1016/j.canlet.2017.09.018 – volume: 70 start-page: 440 year: 2010 ident: B8 article-title: Drug combination studies and their synergy quantification using the Chou-Talalay method. publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-09-1947 – volume: 4 year: 2014 ident: B6 article-title: Posttranslational regulation of Akt in human cancer. publication-title: Cell Biosci. doi: 10.1186/2045-3701-4-59 – volume: 120 start-page: 137 year: 2005 ident: B44 article-title: GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity. publication-title: Cell doi: 10.1016/j.cell.2004.11.012 – volume: 40 start-page: 78 year: 2014 ident: B1 article-title: Adjuvant therapy for resectable pancreatic adenocarcinoma: review of the current treatment approaches and future directions. publication-title: Cancer Treat. Rev. doi: 10.1016/j.ctrv.2013.05.008 – volume: 16 start-page: 358 year: 1997 ident: B20 article-title: Bcl-2 and Bax function independently to regulate cell death. publication-title: Nat. Genet. doi: 10.1038/ng0897-358 – volume: 33 start-page: 10 year: 2012 ident: B19 article-title: Drug discovery from plant sources: an integrated approach. publication-title: Ayu doi: 10.4103/0974-8520.100295 – volume: 362 start-page: 1605 year: 2010 ident: B14 article-title: Pancreatic cancer. publication-title: N. Engl. J. Med. doi: 10.1056/NEJMra0901557 – volume: 10 year: 2010 ident: B4 article-title: Chemopreventive potential of beta-sitosterol in experimental colon cancer model—an in vitro and in vivo study. publication-title: BMC Complement. Altern. Med. doi: 10.1186/1472-6882-10-24 – reference: 33658921 - Front Pharmacol. 2020 Nov 20;11:565535 |
| SSID | ssj0000399364 |
| Score | 2.4103587 |
| Snippet | β-sitosterol (BS), a major bioactive constituent present in plants, has shown potent anti-cancer activity against many human cancer cells, but its activity in... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 1525 |
| SubjectTerms | AKT apoptosis EMT gemcitabine pancreatic cancer Pharmacology β-sitosterol |
| SummonAdditionalLinks | – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtNAEF5BuXBB_GMoaJFQJaS6sb3rnxwQCiVtAQVVSiP1Zu2fE4vUThMX4RvvwJv0EXiAPgRPwszaTQiKOHH17o7XOzM7M96dbwh5BRbE11KC8MpIulx4mSulFC5jJlICi29zTE4efI6ORvzjaXi6So9uF3CxMbTDelKj-XTv23n9FhT-DUacYG872WwiENrTT_Y8LOdzk9wCuxSjmg5aZ9_uy2iLI96cVW4cuGabLIT_Jr_z7-uTf9ijg7vkTutI0l7D-Xvkhinuk53jBom63qUnq8SqxS7doccrjOr6Afl5dekOQZkRJqGcUlFoemjOVF4JiJQN7WPZ7LyiwxpTAy2WM-0VVe7C3tG4mYruo7zMaU819SeorOmg1LYaWDGmvVk5A_L5wtL-UFh62NCfYRbIFMT-1_cfA8x9UpP6DL7EWk17gQxJvTeYcfG1Jfal6hwOP7ns6pIO8zHGDsX4IRkd9E_2j9y2nIOreBRUwH4lTMw0057kWRR4UgjDdcxDATtJEhtwVb1YSS24J4wKdBIGXDHwR7WMuJbsEdkqysI8IdQ3DNxQIyIZYMTFksT4Kok1T4TomsxzSOeakalqsc6x5MY0hZgHWZ9a1qfI-tSy3iGvlyNmDc7HP_q-Q9lY9kOEbvugnI_TVuHTDEwQ10yYUAgeGwWReKQyHeuEeVkWKIe8vJasFDQaj2lEYcqLRRrgHhngiZhDHjeStnwVBniI-uWQeE0G1-ay3lLkE4saHjHm87D79H9M_hm5DcvRtb-ikm2yVc0vzHNwzir5wurcb2ChQ-0 priority: 102 providerName: Scholars Portal |
| Title | β-Sitosterol and Gemcitabine Exhibit Synergistic Anti-pancreatic Cancer Activity by Modulating Apoptosis and Inhibiting Epithelial–Mesenchymal Transition by Deactivating Akt/GSK-3β Signaling |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/30670971 https://www.proquest.com/docview/2179426657 https://pubmed.ncbi.nlm.nih.gov/PMC6331459 https://doaj.org/article/f1464d3ae5aa47ec8256cfd7d830ff2c |
| Volume | 9 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LbtNAFB1VXbFBvDEvDRKqhFQT2zN-ZBlK2lIUVCmt1J01LycW6dhqXCTv-Af-pJ_AB_Qj-BLuHbtpghBs2Hjhx_XE98x9ZOaeS8gb8CChlhLAKxPpcxEUvpRS-IyZRAlsvs2xOHnyOTk85Udn8dlaqy_cE9bRA3cfblDAVOaaCRMLwVOjIKNJVKFTnbGgKCKF1hd83loy5Www-t2Ed-uSkIUNB0U9F8j_GWbvAuz5s-GHHF3_n2LM37dKrvme_Xvkbh800lE32Ptky9gHZOe4Y51ud-nJbRHVcpfu0ONbPur2IflxfeVPYeIiJUK1oMJqemDOVdkIyIoNHWOL7LKh0xbLAB1vMx3ZpvTBTnQhpaJ7iI0LOlJdrwkqWzqptOv8ZWd0VFc1iC-XTvZH6-ThhXGNFR8LgPjPb98nWOek5u05_BLnId1mMRT1wWB1xdde2JdmcDD95LPrKzotZ5gn2Nkjcro_Ptk79PvWDb7iSdSAqpUwKdNMB5IXSRRIIQzXKY8FWI0sNRCWBqmSWvBAGBXpLI64YhB7agnqluwx2baVNU8JDQ2DkNOIREaYXbEsM6HKUs0zIYamCDwyuFFkrnpec2yvscghv0HV5071Oao-d6r3yNvVE3XH6fGXe98jNlb3IRu3OwEYzXuM5v_CqEde3yArh9mLSzLCmupymUdoDyNc_fLIkw5pq1dhMocMXx5JNzC4MZbNK7acO4bwhLGQx8Nn_2Pwz8kd-BxD97dT9oJsNxeX5iUEYo185eYcHCc8-wXuqD1H |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%CE%B2-Sitosterol+and+Gemcitabine+Exhibit+Synergistic+Anti-pancreatic+Cancer+Activity+by+Modulating+Apoptosis+and+Inhibiting+Epithelial%E2%80%93Mesenchymal+Transition+by+Deactivating+Akt%2FGSK-3%CE%B2+Signaling&rft.jtitle=Frontiers+in+pharmacology&rft.au=Zhang-qi+Cao&rft.au=Xue-xi+Wang&rft.au=Li+Lu&rft.au=Jing-wen+Xu&rft.date=2019-01-08&rft.pub=Frontiers+Media+S.A&rft.eissn=1663-9812&rft.volume=9&rft_id=info:doi/10.3389%2Ffphar.2018.01525&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_f1464d3ae5aa47ec8256cfd7d830ff2c |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1663-9812&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1663-9812&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1663-9812&client=summon |